Additional FGFR-targeted agents have reported clinical benefit in patients with pretreated CCA harbouring FGFR2 fusions/rearrangements: infigratinib,38,39 derazantinib,40, 60 lirafugratinib,41 and tinengotinib.42 This evidence concerns the gene FGFR2 and cholangiocarcinoma.